Clinical Trials · NCT00313001
Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 373
- Start date
- Apr 2006
- Locations
- 1 site, United States
- Primary endpoint
- Superiority as assessed by HbA1c reduction